7 results about "Atresia" patented technology

The present application relates to the technical field of medical devices, and discloses an esophageal closure device, which comprises an upper extension head, a lower extension head, a sleeve, a pull rope, a fistula seat and a pull rope adjusting unit, the sleeve is installed between the lower extension head and the pull rope adjusting unit, the pull rope adjusting unit comprises a base, a knob and a take-up post, the base is connected with the fistula seat, the knob is arranged on the base, the take-up post is arranged in the knob, the upper end of the sleeve is connected with the base, and the lower end of the sleeve is connected with the lower extension head, the pull rope passes through the sleeve, the upper end of the pull rope is fixedly connected with the take-up post, and the lower end of the pull rope is fixedly connected with the upper extension head, upper and lower opposing bevels are arranged on the upper extension head and the lower extension head respectively, and the upper opposing bevel and the lower opposing bevel are matched when the upper extension head and the lower extension head are joined. The present application accelerates the growth of the blind end of the esophagus with esophageal atresia, and simultaneously increases the cross-sectional area and the circumference of the esophageal junction.

A tissue expansion sleeve comprising a tube formed of woven polymer; the woven polymer forming helical trusses; and a biologically active material disposed on an outer surface of the tube.

The application relates to a method for establishing an early ovarian failure rat model, which comprises the following steps: taking healthy rats, and performing gavage on the rats according to a dosage of 10-20 mg / Kg of a phytostilbene preparation, wherein the dosage is the ratio of phytostilbene to the weight of the rats, and obtaining the early ovarian failure rat model after four days of administration. The early ovarian failure rat model is obtained by performing gavage on the rats after the phytostilbene preparation, the model is simple to establish, and the model establishment time is short. Through ovarian pathological observation, it can be seen that the simulated animal model has obvious ovary tissue damage, follicular granulosa cell destruction and apoptosis, and follicle atresia and other symptoms. The obtained model has good stability and repeatability. The phytostilbene is used to successfully establish the early ovarian failure rat model, lays a good foundation for establishing a stable early ovarian failure model for basic research, and provides a reliable method for the construction of the early ovarian failure model.

The invention provides an application of an E3 ubiquitin ligase RLIM gene inhibitor in preparation of a medicine for treating ovarian aging or injury. Experiments find that the expression level of the RLIM gene in the ovary is positively correlated with the aging degree, and the expression of the RLIM gene is remarkably improved along with age increase. In-vivo and in-vitro experiments show that ovarian granular cell senescence can be effectively delayed and ovarian functions can be improved by inhibiting RLIM expression, and particularly, the proportion of atresia follicles is reduced, the number of healthy follicles is increased, and serum AMH and E2 levels are remarkably improved. The pharmaceutical composition provided by the invention comprises a siRNA inhibitor (preferably, siRLIM-2) of specific targeting RLIM and a nano-liposome carrier, and efficient targeting delivery can be realized through tail vein injection. The treatment scheme has no toxic effect on important organs, is high in safety, and provides a new effective means for treatment of ovarian aging and related diseases.

The invention relates to the technical field of medical apparatus and instruments, and discloses an esophageal atresia ultrasonic range finder which is used for measuring long segment deletion type esophageal atresia of infants and comprises an ultrasonic array module, a navigation coupling module and a signal processing module. According to the method, a high-resolution blind end three-dimensional form is obtained through an intracavity self-adaptive fitting scanning and synthetic aperture focusing technology, the optimal measurement basis is dynamically determined by fusing spatial attitude data, the shortest path distance of a three-dimensional space is finally calculated, and measurement errors of in-vitro ultrasound and two-dimensional images are avoided; real-time measurement data and spatial position information are fused and presented, so that an intuitive form and length change trend is provided for a doctor, and the confidence and accuracy of a treatment decision are enhanced; automatic processes from data acquisition and processing to result output are integrated, the operation difficulty and the human intervention intensity are reduced, objective, quantitative and visual decision support is provided for clinicians to evaluate the curative effect of the esophageal extension surgery and select the optimal surgery opportunity, and the diagnosis and treatment efficiency and repeatability are improved.

The invention relates to an electrostatic spinning-photocuring composite tubular stent. The electrostatic spinning-photocuring composite tubular stent comprises a core, a shell and a coating layer, the core comprises polylactic acid and valine acid, the shell comprises polyvinyl butyral and a YAP agonist, and the coating layer comprises methacrylated hyaluronic acid and geniposide; the shell wraps the surface of the core, and the coating layer wraps the surface of the shell; the YAP agonist comprises C381 (C381). The preparation method comprises the following steps: preparation of the core-shell tubular stent and wrapping of the coating layer. According to the electrostatic spinning-photocuring composite tubular stent, a bile duct repair integrated platform which is free of acidification degradation, high in encapsulation efficiency, bionic in surface and capable of achieving three-medicine space-time synergy is achieved for the first time, and a breakthrough tissue engineering solution capable of being sewn, degraded and actively regenerated is provided for intractable bile diseases such as PSC and bile duct atresia.

The application aims to provide a new application of an iron death inhibitor, Liproxstatin-1. The application studies the iron death phenomenon in the process of follicle atresia of laying poultry, finds that the iron death inhibitor Liproxstatin-1 can rescue the follicular granulosa cell death induced by tamoxifen (TMX), can inhibit the oxidative stress level and intracellular iron ion overload caused by TTMX treatment, can effectively inhibit the follicular iron death phenomenon induced by TTMX, and finally can restore the egg production function of livestock and poultry, and has the development into a drug for treating follicle atresia and used for treating follicle atresia of livestock and poultry.